What is the 13F Pro Quality Score for NMRA?

13F Pro ranks Neumora Therapeutics, Inc. (NMRA) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View NMRA's current score at https://13fpro.ai/research/NMRA (free sign-up required for the full ranking).

Which hedge funds own the most NMRA stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of NMRA include Siren, L.L.C., SOFTBANK GROUP, PERCEPTIVE ADVISORS. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/NMRA as soon as new 13F filings post.

Where does 13F Pro source NMRA data?

All Neumora Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Neumora Therapeutics, Inc. files with the SEC under CIK 1885522. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is NMRA in?

Neumora Therapeutics, Inc. (NMRA) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is NMRA research updated on 13F Pro?

NMRA's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Neumora Therapeutics, Inc.(NMRA)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1885522 NMRA stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

NMRA Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Neumora Therapeutics, Inc. (NMRA), a Healthcare sector company. NMRA is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), Neumora Therapeutics, Inc. reports net income of $-53.5M, free cash flow of $-46.4M. Top institutional holders of NMRA by reported 13-F value include Siren, L.L.C., SOFTBANK GROUP, PERCEPTIVE ADVISORS, based on the most recent SEC filings. NMRA trades on the Nasdaq exchange and files with the SEC under CIK 1885522. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NMRA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Neumora Therapeutics, Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-53.5M

Free Cash Flow

Q1 2026

$-46.4M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Net Income

+203.3% YoY

$243.8MFY 2024

FY22 $-130.9MFY23 $-235.9MFY24 $243.8M

Operating Income

-4.5% YoY

$-263.5MFY 2024

FY22 $-135.9MFY23 $-252.1MFY24 $-263.5M

EPS (Diluted)

+57.9% YoY

$-1.53FY 2024

FY22 $-0.96FY23 $-3.63FY24 $-1.53

Total Assets

-36.1% YoY

$317.0MFY 2024

FY22 $426.2MFY23 $496.2MFY24 $317.0M

Total Debt

$0.00FY 2024

FY22 —FY23 —FY24 $0.00

Op. Cash Flow

-12.0% YoY

$-182.9MFY 2024

FY22 $-114.9MFY23 $-163.3MFY24 $-182.9M

Metric	FY 2024	FY 2023	FY 2022
Net Income	$243.8M +203.3%	$-235.9M -80.2%	$-130.9M
Operating Income	$-263.5M -4.5%	$-252.1M -85.5%	$-135.9M
EPS (Diluted)	$-1.53 +57.9%	$-3.63 -277.3%	$-0.96
Total Assets	$317.0M -36.1%	$496.2M +16.4%	$426.2M
Total Debt	$0.00	—	—
Operating Cash Flow	$-182.9M -12.0%	$-163.3M -42.1%	$-114.9M

AI Insight: NMRA Financial Trends

Equity has eroded 81% from $381M to $71M over eight quarters as Neumora burns cash with zero revenue and debt surged to $113M.

• Equity collapsed from $381M in Q2 2024 to $71M in Q1 2026, an $310M deterioration driven by uninterrupted net losses.

• Total debt jumped from zero prior to Q2 2025 to $115M in Q4 2025, then held at $113M in Q1 2026, signaling new leverage.

• Operating cash burn moderated slightly; Q1 2026 outflow of $46M compares favorably to the $59M peak burn in Q1 2025.

• No revenue recorded across all eight quarters — company remains entirely pre-commercial and dependent on external financing.

⚠ Equity at $71M with ~$48–$53M quarterly cash burn implies fewer than two quarters of buffer before equity is exhausted.

⚠ Debt tripled from $40M in Q3 2025 to $115M in Q4 2025 — monitor terms and covenants as leverage rises sharply.

⚠ Any clinical data readout or partnership deal could rapidly shift the financing runway — key binary catalyst to watch.

AI Insight: NMRA Ratio Trends

Neumora's return metrics have deteriorated sharply while D/E has surged 7x from 0.22 to 1.60 in three quarters, signaling rapidly increasing financial stress.

• ROE worsened from -61.6% in Q2 2024 to -171.8% in Q3 2025, reflecting deepening losses relative to equity.

• ROA deteriorated from -58.1% in Q2 2024 to -94.2% in Q2 2025, indicating assets generating increasingly larger losses.

• D/E ratio surged from 0.22 in Q2 2025 to 1.60 by Q1 2026, a 7x increase in just three quarters.

⚠ D/E at 1.60 as of Q1 2026 — monitor whether debt issuance continues accelerating as cash burn persists.

⚠ OpMargin and NPM remain entirely unreported across all periods — absence limits full profitability assessment.

Get alerted when NMRA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Neumora Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of NMRA

Siren, L.L.C.
$16.6M8,497,822 sh
SOFTBANK GROUP CORP.
$11.9M6,090,301 sh
PERCEPTIVE ADVISORS LLC
$10.0M5,104,097 sh
MIC Capital Management UK LLP
$8.7M4,460,700 sh
VANGUARD CAPITAL MANAGEMENT LLC
$7.6M3,891,893 sh
FMR LLC
$6.8M3,498,658 sh
WELLCOME TRUST LTD (THE) as trustee of the WELLCOME TRUST
$6.5M3,309,123 sh
MILLENNIUM MANAGEMENT LLC
$5.4M2,754,854 sh
ICONIQ Capital, LLC
$5.0M2,559,090 sh
Lunate Capital Ltd
$4.1M2,124,143 sh

Fund	Value	Shares
Siren, L.L.C.	$16.6M	8,497,822
SOFTBANK GROUP CORP.	$11.9M	6,090,301
PERCEPTIVE ADVISORS LLC	$10.0M	5,104,097
MIC Capital Management UK LLP	$8.7M	4,460,700
VANGUARD CAPITAL MANAGEMENT LLC	$7.6M	3,891,893
FMR LLC	$6.8M	3,498,658
WELLCOME TRUST LTD (THE) as trustee of the WELLCOME TRUST	$6.5M	3,309,123
MILLENNIUM MANAGEMENT LLC	$5.4M	2,754,854
ICONIQ Capital, LLC	$5.0M	2,559,090
Lunate Capital Ltd	$4.1M	2,124,143

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put NMRA on your watchlist

Track score changes the day Neumora Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is NMRA a good stock to buy?

13F Pro's AI-powered analysis of Neumora Therapeutics, Inc. (NMRA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for NMRA are available on the NMRA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own NMRA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling NMRA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Neumora Therapeutics, Inc.'s investment landscape.